Skip to main content

Table 1 Patients’ data

From: Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts

ID Tumor Agea BMI Ca12–5 HE4 Stage
26 HGSOC 50′s–60′s 18.7 979 999 IIIA1 (i)
09 HGSOC 40′s–50′s 22.3 541 485 IIIB
34 HGSOC 50′s–60′s 25.0 1616 196 IIIB
28 HGSOC 50′s–60′s 33.0 1389 388 IIIC
30 HGSOC 50′s–60′s 25.4 867 979 IVB
46 HGSOC 50′s–60′s 32.6 807 220 IVB
65 HGSOC 60′s–70′s 36.4 1551 832 IVB
23 HGSOC 70′s–80′s 27.3 416 1500  ≥ IIICb
39 HGSOC 70′s–80′s 18.1 680 766 IVB
   md 58
av 59
md 25.4
av 27.0
md 867
av 983
md 766
av 707
 
55 Cystadenoma 50′s–60′s 24.7 76 53  
17 Cystadenoma 40′s–50′s 23.9 24 164  
61 Cystadenoma 40′s–50′s 26.6 35 34  
32 Tecoma 70′s–80′s 25.1 173 NA  
35 Fibroma 50′s–60′s 37.2 69 NA  
63 Fibroma 80′s–90′s 26.6 126 56  
36 Teratoma 40′s–50′s NA 152 46  
   md 53
av 56
md 25.8
av 27.3
md 65
av 70
md 53
av 68
 
  1. The data of the patients gathered at the stage of diagnosis and after the surgery
  2. aThe age of the participants is presented as a range in order to protect their anonymity, BMI, body mass index, Ca12-5, plasma Ca12-5 antigen value; HE4, plasma human epididymal antigen 4 value; Stage, stage of the ovarian cancer according to FIGO 2016 guidelines, HGSOC, high-grade serous ovarian cancer; b Inoperable patient, no thorough staging operation. md, median; av, average; NA, Not available